A0A6D2W501 (A0A6D2W501_PANTR) Pan troglodytes (Chimpanzee)
Protein cereblon UniProtKBInterProInteractive Modelling
442 aa; Sequence (Fasta) ;
3 identical sequences: Homo sapiens: Q96SW2; Pan troglodytes: H2R8H3; Pan paniscus: A0A2R9CKP4
It is possible new templates exist for this target since these models were created.
Available Structures
36 Experimental Structures
Description | PDB ID | Oligo-state | Range | Ligands | ||
---|---|---|---|---|---|---|
Structure of the DDB1-CRBN-pomalidomide complex bound to ZNF692(ZF4) |
Heteromer Q16531; Q96SW2; Q9BU19; | 2×ZN; 1×Y70; | ||||
Assess | ||||||
Crystal structure of human CRBN-DDB1 in complex with Pomalidomide |
Heteromer Q16531; Q96SW2; | 6×EDO; 1×ZN; 1×Y70; | ||||
Assess | ||||||
Cereblon in complex with DDB1, CC-90009, and GSPT1 |
Heteromer P15170; Q16531; Q96SW2; | 1×V4M; 1×ZN; | ||||
Assess | ||||||
Cereblon in complex with DDB1, CC-885, and GSPT1 |
Heteromer P15170; Q16531; Q96SW2; | 1×ZN; 1×85C; | ||||
Assess | ||||||
Structural basis of Lenalidomide induced CK1a degradation by the crl4crbn ubiquitin ligase |
Heteromer P48729; Q16531; Q96SW2; | 1×ZN; 1×LVY; | ||||
Assess | ||||||
Crystal structure of DDB1-CRBN-ALV1 complex bound to Helios (IKZF2 ZF2) |
Heteromer Q16531; Q96SW2; Q9UKS7; | 2×ZN; 1×RN9; | ||||
Assess | ||||||
Crystal structure of human CRBN-DDB1 in complex with compound 4 |
Heteromer Q16531; Q96SW2; | 9×EDO; 1×ZN; 1×VP9; | ||||
Assess | ||||||
Crystal structure of DDB1-CRBN-BRD4(BD1) complex bound to dBET6 PROTAC. |
Heteromer O60885; Q16531; Q96SW2; | 1×ZN; 1×RN6; | ||||
Assess | ||||||
Crystal structure of DDB1-CRBN-BRD4(BD1) complex bound to dBET23 PROTAC. |
Heteromer O60885; Q16531; Q96SW2; | 1×ZN; 1×RN3; | ||||
Assess | ||||||
Crystal structure of DDB1-CRBN-BRD4(BD1) complex bound to dBET70 PROTAC |
Heteromer O60885; Q16531; Q96SW2; | 1×ZN; | ||||
Assess | ||||||
Cereblon~DDB1 bound to CC-92480 with DDB1 in the hinged conformation |
Heteromer Q16531; Q96SW2; | 1×ZN; 1×QFC; | ||||
Assess | ||||||
Cereblon~DDB1 bound to CC-92480 with DDB1 in the linear conformation |
Heteromer Q16531; Q96SW2; | 1×ZN; 1×QFC; | ||||
Assess | ||||||
Cereblon~DDB1 bound to CC-92480 with DDB1 in the twisted conformation |
Heteromer Q16531; Q96SW2; | 1×ZN; 1×QFC; | ||||
Assess | ||||||
Cryo-EM structure of DDB1dB:CRBN:PT-179:SD40, conformation 2 |
Heteromer Q13422; Q16531; Q96SW2; | 2×ZN; 1×MIQ; | ||||
Assess | ||||||
Cereblon in complex with DDB1 and CC-220 |
Heteromer Q16531; Q96SW2; | 1×8W7; 1×ZN; | ||||
Assess | ||||||
Structure with SJ3149 |
Heteromer P48729; Q16531; Q96SW2; | 1×ZN; 1×YOT; | ||||
Assess | ||||||
Crystal Structure of Human Cereblon in Complex with DDB1 and Lenalidomide |
Heteromer Q16531; Q96SW2; | 1×ZN; 1×LVY; | ||||
Assess | ||||||
Cereblon~DDB1 bound to Iberdomide and Ikaros ZF1-2-3 |
Heteromer Q13422; Q16531; Q96SW2; | 2×ZN; 1×8W7; | ||||
Assess | ||||||
Cereblon-DDB1 bound to CC-92480 and Ikaros ZF1-2-3 |
Heteromer Q13422; Q16531; Q96SW2; | 2×ZN; 1×QFC; | ||||
Assess | ||||||
Cereblon~DDB1 bound to Pomalidomide |
Heteromer Q16531; Q96SW2; | 1×ZN; 1×Y70; | ||||
Assess | ||||||
Structural Basis for Thalidomide Teratogenicity Revealed by the Cereblon-DDB1-SALL4-Pomalidomide Co… |
Heteromer Q16531; Q96SW2; Q9UJQ4; | 2×ZN; 1×Y70; | ||||
Assess | ||||||
Cryo-EM structure of DDB1dB:CRBN:PT-179:SD40, conformation 1 |
Heteromer Q13422; Q16531; Q96SW2; | 2×ZN; 1×MIQ; | ||||
Assess | ||||||
Ternary complex structure of Cereblon-DDB1 bound to IKZF2(ZF2) and the molecular glue DKY709 |
Heteromer Q16531; Q53SU9; Q96SW2; | 2×ZN; 1×LWK; 4×SO4; | ||||
Assess | ||||||
Structure of DDB1-CRBN-pomalidomide complex bound to IKZF1(ZF2) |
Heteromer Q13422; Q16531; Q96SW2; | 2×ZN; 1×Y70; | ||||
Assess | ||||||
Ternary complex structure of Cereblon-DDB1 bound to IKZF2(ZF2,3) and the molecular glue DKY709 |
Heteromer Q16531; Q96SW2; Q9UKS7; | 3×ZN; 1×LWK; | ||||
Assess | ||||||
The ternary complex structure of DDB1-CRBN-SALL4(ZF1,2)-short bound to CC-220 |
Heteromer Q16531; Q96SW2; Q9UJQ4; | 3×ZN; 1×8W7; 6×SO4; | ||||
Assess | ||||||
Cereblon-DDB1 in the Apo form with DDB1 in the twisted conformation |
Heteromer Q16531; Q96SW2; | 1×ZN; | ||||
Assess | ||||||
Cereblon-DDB1 in the Apo form |
Heteromer Q16531; Q96SW2; | 1×ZN; | ||||
Assess | ||||||
Cereblon~DDB1 in the Apo form with DDB1 in the hinged conformation |
Heteromer Q16531; Q96SW2; | 1×ZN; | ||||
Assess | ||||||
Crystal structure of DDB1-CRBN-BRD4(BD1) complex bound to dBET57 PROTAC |
Heteromer O60885; Q16531; Q96SW2; | 1×ZN; | ||||
Assess | ||||||
The ternary complex structure of DDB1-CRBN-SALL4(ZF1,2)-short bound to Pomalidomide |
Heteromer Q16531; Q96SW2; Q9UJQ4; | 3×ZN; 1×Y70; | ||||
Assess | ||||||
The ternary complex structure of DDB1-CRBN-SALL4(ZF1,2)-long bound to Pomalidomide |
Heteromer Q16531; Q96SW2; Q9UJQ4; | 3×ZN; 1×Y70; | ||||
Assess | ||||||
Cryo-EM structure of DDB1dB:CRBN:Pomalidomide:SD40 |
Heteromer Q13422; Q16531; Q96SW2; | 2×ZN; 1×Y70; | ||||
Assess | ||||||
Cereblon in complex with SALL4 and (S)-5-hydroxythalidomide |
Heteromer Q96SW2; Q9UJQ4; | 1×F4U; 2×ZN; 2×SO4; | ||||
Assess | ||||||
Cereblon in complex with SALL4 and (S)-thalidomide |
Heteromer Q96SW2; Q9UJQ4; | 1×EF2; 2×ZN; | ||||
Assess | ||||||
crystal structure of hN33/Tusc3-peptide 1 |
Heteromer Q13454; Q96SW2; | |||||
Assess |
2 SWISS-MODEL models
Template | Oligo-state | QMEANDisCo | Range | Ligands | Trg-Tpl Seq id (%) | |
---|---|---|---|---|---|---|
8tnr.1.B | monomer | 0.81 | 1×ZN; | 100.00 | ||
Assess | ||||||
8d7x.1.B | monomer | 0.71 | 1×ZN; | 100.00 | ||
Assess |